JP2008526830A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526830A5
JP2008526830A5 JP2007549979A JP2007549979A JP2008526830A5 JP 2008526830 A5 JP2008526830 A5 JP 2008526830A5 JP 2007549979 A JP2007549979 A JP 2007549979A JP 2007549979 A JP2007549979 A JP 2007549979A JP 2008526830 A5 JP2008526830 A5 JP 2008526830A5
Authority
JP
Japan
Prior art keywords
enantiomer
finding
racemic ketoconazole
inventionsome
racemate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007549979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526830A (ja
JP5358095B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/000026 external-priority patent/WO2006072881A1/en
Publication of JP2008526830A publication Critical patent/JP2008526830A/ja
Publication of JP2008526830A5 publication Critical patent/JP2008526830A5/ja
Application granted granted Critical
Publication of JP5358095B2 publication Critical patent/JP5358095B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007549979A 2005-01-10 2006-01-10 糖尿病、メタボリック症候群、および他の状態を治療するための方法および組成物 Expired - Lifetime JP5358095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64305505P 2005-01-10 2005-01-10
US60/643,055 2005-01-10
PCT/IB2006/000026 WO2006072881A1 (en) 2005-01-10 2006-01-10 Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Publications (3)

Publication Number Publication Date
JP2008526830A JP2008526830A (ja) 2008-07-24
JP2008526830A5 true JP2008526830A5 (cg-RX-API-DMAC7.html) 2012-12-20
JP5358095B2 JP5358095B2 (ja) 2013-12-04

Family

ID=36143322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007549979A Expired - Lifetime JP5358095B2 (ja) 2005-01-10 2006-01-10 糖尿病、メタボリック症候群、および他の状態を治療するための方法および組成物

Country Status (20)

Country Link
US (6) US20090233843A1 (cg-RX-API-DMAC7.html)
EP (1) EP1853266B1 (cg-RX-API-DMAC7.html)
JP (1) JP5358095B2 (cg-RX-API-DMAC7.html)
KR (2) KR101387910B1 (cg-RX-API-DMAC7.html)
CN (1) CN101141964B (cg-RX-API-DMAC7.html)
AT (1) ATE528005T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006204334B2 (cg-RX-API-DMAC7.html)
CA (1) CA2594433C (cg-RX-API-DMAC7.html)
CY (1) CY1112519T1 (cg-RX-API-DMAC7.html)
DK (1) DK1853266T3 (cg-RX-API-DMAC7.html)
ES (1) ES2377526T3 (cg-RX-API-DMAC7.html)
IL (1) IL184459A (cg-RX-API-DMAC7.html)
MX (1) MX2007008331A (cg-RX-API-DMAC7.html)
NO (1) NO339007B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ560481A (cg-RX-API-DMAC7.html)
PL (1) PL1853266T3 (cg-RX-API-DMAC7.html)
PT (1) PT1853266E (cg-RX-API-DMAC7.html)
SI (1) SI1853266T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006072881A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200706020B (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
CN101141964B (zh) * 2005-01-10 2013-06-05 科尔泰多投资公司 治疗糖尿病、代谢综合症和其它病症的组合物及方法
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
RU2009116632A (ru) 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
RU2337675C1 (ru) * 2007-04-05 2008-11-10 Илья Николаевич Медведев Способ нормализации первой фазы свертывания крови при метаболическом синдроме
RU2337686C1 (ru) * 2007-04-05 2008-11-10 Илья Николаевич Медведев Способ оптимизации активности тромбоцитов при метаболическом синдроме
RU2337680C1 (ru) * 2007-04-05 2008-11-10 Илья Николаевич Медведев Способ восстановления функций тромбоцитов при метаболическом синдроме
RU2337683C1 (ru) * 2007-04-05 2008-11-10 Илья Николаевич Медведев Способ снижения активности кровяных пластинок при метаболическом синдроме
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2547793A4 (en) * 2010-03-15 2013-08-21 Univ Duke IDENTIFICATION OF A GENETIC RISK FACTOR FOR DIABETES
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US10272133B2 (en) 2011-10-06 2019-04-30 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
EP2763688B1 (en) 2011-10-06 2018-06-27 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
EP2953625A1 (en) * 2013-02-06 2015-12-16 Cortendo AB (publ) Novel functionalized 4-(phenoxymethyl(-1,3-dioxolane analogs exhibiting cytochrome p450 inhibition and their method of use
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
SG10201707324WA (en) * 2013-03-12 2017-10-30 Hmi Inc Plant extracts with anti-diabetic and other useful activities
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
CN103432135A (zh) * 2013-09-06 2013-12-11 天津市康婷生物工程有限公司 一种内源性洋地黄样因子抑制剂
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
US20170151202A1 (en) * 2015-09-09 2017-06-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
CN105441391A (zh) * 2015-12-10 2016-03-30 湖南中医药大学 一种糖尿病并发抑郁症的细胞模型及建立方法和应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
KR102114705B1 (ko) 2017-11-06 2020-05-25 연세대학교 산학협력단 스타틴에 의한 약물유해반응의 예방 또는 치료용 약학 조성물
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
KR102294721B1 (ko) 2018-09-28 2021-08-31 경북대학교 산학협력단 티아민 유도체를 포함하는 고코르티솔증 예방 또는 치료용 조성물
EP3863634B1 (en) 2018-10-12 2026-04-08 Strongbridge Dublin Limited Levoketoconazole for treatment of congenital adrenal hyperplasia
EP3934649A4 (en) 2019-03-04 2022-11-23 Strongbridge Dublin Limited METHODS OF TREATMENT OF DISEASES WITH LEVOKETOCONAZOLE
WO2020231909A1 (en) * 2019-05-11 2020-11-19 Steven Hoffman Compositions and methods for treating bile acid associated diseases
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
BR112022016494A2 (pt) * 2020-02-19 2022-10-11 New Frontier Labs Llc Ésteres de ácido azelaico no tratamento ou prevenção da dislipidemia e condições associadas
KR102289381B1 (ko) * 2020-03-17 2021-08-17 주식회사 대웅테라퓨틱스 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4525870A4 (en) * 2022-05-20 2026-05-06 Corcept Therapeutics Inc METHODS FOR TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND FOR REDUCING THE LIVER TOXICITY OF OTHER MEDICINES ADMINISTERED TO A PATIENT
WO2024040256A2 (en) * 2022-08-19 2024-02-22 National Health Research Institutes Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases
EP4619398A1 (en) * 2022-11-14 2025-09-24 Piramal Pharma Limited A process for the preparation of levoketoconazole

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
WO1994014447A1 (en) * 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
WO1994014446A1 (en) 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections
US5869255A (en) * 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
ATE244009T1 (de) * 1994-08-09 2003-07-15 Metabolic Syndrome I Gbg Ab Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
US5584790A (en) 1995-09-08 1996-12-17 Beckman Instruments, Inc. Variable inclination centrifugation assembly for rapid separation of blood
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
ATE272650T1 (de) 1999-03-29 2004-08-15 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
CA2369549A1 (en) 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
AU4537900A (en) 1999-05-17 2000-12-05 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
DE60039111D1 (de) 1999-09-28 2008-07-17 Bayer Corp Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
MXPA04007713A (es) * 2002-02-07 2004-11-10 Pfizer Uso de inhibidores de la fosfodiesterasa tipo 5, tal como sildenafil, en el tratamiento del sindrome de ovario poliquistico.
WO2004080414A2 (en) * 2003-03-12 2004-09-23 Mullally John P Composition and method for treating inflammations by reducing c-reactive protein
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CN101141964B (zh) * 2005-01-10 2013-06-05 科尔泰多投资公司 治疗糖尿病、代谢综合症和其它病症的组合物及方法
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
RU2009116632A (ru) * 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей

Similar Documents

Publication Publication Date Title
WO2005079851A3 (en) Dopamine-agonist combination therapy with sedatives for improving sleep quality
NZ606805A (en) Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
JP2010513478A5 (cg-RX-API-DMAC7.html)
JP2011524906A5 (cg-RX-API-DMAC7.html)
JP2007523049A5 (cg-RX-API-DMAC7.html)
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
NZ594163A (en) Pyranose derivatives of pestcidal 1,2,4-triazoles
JP2010285439A5 (cg-RX-API-DMAC7.html)
DK1879873T3 (da) Neuroterapeutiske azolforbindelser
EA200970396A1 (ru) Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
JP2009543793A5 (cg-RX-API-DMAC7.html)
AR059430A1 (es) Novedosas combinaciones y metodos de inhibidores del vhc
JP2007523135A5 (cg-RX-API-DMAC7.html)
DE602006003409D1 (de) Videospielvorrichtung und Speichermedium, das Videospielprogramm speichert
DE602005009991D1 (de) Paketverfolgung unter Anwendung von dynamischen Paketfiltern
JP2008531742A5 (cg-RX-API-DMAC7.html)
WO2010005980A8 (en) Tacrolimus for improved treatment of transplant patients
BRPI0507897B8 (pt) formulação de droga sólida
DK2488523T3 (da) N-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazol[1,5-a]1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamid, en dobbeltmodulator af chemokinreceptor-aktivitet, krystallinske former ogfremgangsmåder
EP1770085A4 (en) DIAMIDE DERIVATIVE, PREPARATION METHOD AND FUNGICIDE WITH THE DERIVATIVE AS ACTIVE AGENT
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
CL2008003358A1 (es) Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos.
EP2096869A4 (en) VIDEO PROCESSING AND DEVICE, VIDEO PROCESSING PROGRAM THEREFOR AND STORAGE MEDIUM WITH THE PROGRAM
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome